Myocardial fibrosis

Biomarker

1 paper

  • Animals1

Latest

Nov 2025: 7Dec 2025: 4Jan 2026: 1Feb 2026: 3Mar 2026: 1Apr 2026: 1May 2026: 3Jun 2026: 4Jul 2026: 3Aug 2026: 3Sep 2026: 11Oct 2026: 344 in 12 months
European Heart Journal Cardiovascular Pharmacotherapy

Dapagliflozin did not improve heart relaxation in small trial

A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.A heart-relaxation measure stayed at 6.2 with dapagliflozin, versus 6.6 to 6.7 with placebo, in a 32-person randomised trial.

Randomised trial in 29 patients with HFpEF, 13 weeks, against placeboDapagliflozin

Limit: Only 29 patients completed the protocol, limiting power to detect improved relaxation

Aging Cell

Restoring a protein partly improves heart function in mice

Experiments in mice producing a progeria-linked protein in heart muscle cells found that restoring an RNA-marking protein partly reduced abnormal heart changes.Experiments in mice producing a progeria-linked protein in heart muscle cells found that restoring an RNA-marking protein partly reduced abnormal heart changes.

Experiments in Zmpste24−/− mice, 2 months, against AAV-cTnT-GFP-treated miceMechanisms

Limit: Reduced heart fibrosis does not directly demonstrate restored pumping function

Histology and Histopathology

Killifish exhibit distinct structural changes and fibrosis during cardiac aging

Long-lived African turquoise killifish show ventricular enlargement, fibrosis, and reduced myocardial density with age rather than typical cardiomyocyte hypertrophy.Long-lived African turquoise killifish show ventricular enlargement, fibrosis, and reduced myocardial density with age rather than typical cardiomyocyte hypertrophy.

Experiments in killifishMechanisms